DDInter416 DDInter1435
This drug is a broad spectrum antimycotic or antifungal agent. Clotrimazole's antimycotic properties were discovered in the late 1960s. Clotrimazole falls under the _imidazole_ category of _azole_ antifungals, possessing broad-spectrum antimycotic activity. It is available in various preparations, including creams, pessaries, and troche formulations (slowly dissolving tablets). As well as its antifungal activity, clotrimazole has become a drug of interest in treating several other diseases such as sickle cell disease, malaria and some cancers. The minimal side effect profile of this drug and its uncomplicated metabolic profile have led it to gain widespread acceptance for the treatment of mycotic outbreaks such as vaginal yeast infections as well as athlete's foot.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Clotrimazole {u} (Compound) resembles {v} (Compound) Methadone
Clotrimazole {u} (Compound) resembles {v} (Compound) Diphenidol
Clotrimazole {u} (Compound) binds {v} (Gene) CYP2C9
Clotrimazole {u} (Compound) upregulates {v} (Gene) PCK2
Clotrimazole {u} (Compound) is included by {v} (Pharmacologic Class) Azoles
Clotrimazole {u} (Compound) causes {v} (Side Effect) Dermatitis bullous
Clotrimazole (Compound) resembles Methadone (Compound)
Clotrimazole (Compound) resembles Diphenidol (Compound)
Clotrimazole (Compound) binds CYP2C9 (Gene)
Clotrimazole (Compound) upregulates PCK2 (Gene)
Clotrimazole (Compound) is included by Azoles (Pharmacologic Class)
Clotrimazole (Compound) causes Dermatitis bullous (Side Effect)